MedTrace Logo

Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance

NCT03495479 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-10-18

No results posted yet for this study

Summary

Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management. The investigators will assess how OMN54 affects PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will be tested to follow disease evolution.

Conditions

Interventions

DRUG

OMN54

Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.

Sponsors & Collaborators

  • Vancouver Prostate Centre

    collaborator OTHER

  • Omnitura Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Alan So, MD · Prostate Centre at Vancouver General Hospital

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2028-01-31
Completion
2029-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03495479 on ClinicalTrials.gov